ClinicalTrials.gg
RecruitingNCT06879561Updated Dec 2, 2025

Pressure Wire Guidance for Infrapopliteal Artery Interventions

An interventional study of Angiography-guided angioplasty and Pressure wire-guided angioplasty in Chronic Limb-Threatening Ischemia, sponsored by Yonsei University. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Yonsei University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Chronic Limb-Threatening Ischemia with a site in Korea, Republic of — 1 open to participants now, 1 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · Korea, Republic of.

Started
2025
the only one that year
No phase
3 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
4 of 11
Yonsei University

Among the 11 studies in Chronic Limb-Threatening Ischemia with a site in Korea, Republic of, this one is the only one that started in 2025, is one of 3 with no phase, and was the 11th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

1 of the 11 studies in Chronic Limb-Threatening Ischemia with a site in Korea, Republic of is open now.

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Chronic Limb-Threatening Ischemia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

"• A prospective, single-center randomized controlled comparison trial.

  • A total of 100 patients with symptoms of chronic limb-threatening ischemia (Rutherford category 5) undergoing endovascular treatment for anterior tibial artery or posterior tibial artery lesions will be included if they meet the inclusion criteria and do not meet any exclusion criteria.
  • Patients will be randomized in a 1:1 open-label manner either to the pressure wire-guided group or the angiography-guided group.
  • Patients will be treated with balloon angioplasty for anetrior tibial artery or posterior tibial artery lesions.
  • In the angiography-guided group, balloon angioplasty will be performed to achieve an optimal procedural result, as determined by angiography. Optimal results are defined as antegrade blood flow without residual stenosis >50% or flow-limiting dissection.
  • In the Pressure Wire-guided gorup, balloon angioplasty will be performed to obtain optimal procedural result based on both angiography and a pressure gradient over the target lesion. Optimal pressure gradient is less than 10 mmHg by measurement using a Pressure Wire.
  • The primary efficacy endpoint is defined by attaiment of skin perfusion pressure ≥50 mmHg within 1-3 days after the index procedure.
  • Patients will be followed at 1, 3, and 6 months after the procdure to assess wound healing status, and clinical events."
Read the detailed description
  1. Prospective, singlecenter, open label, randomized controlled study
  2. Eligible patients with chronic limb-threatening ischemia (Rutherford category 5) undergoing endovascular treatment for anterior tibial artery or posterior tibial artery lesions will be randomized to pressure wire-guided or angiography-guided groups.
  3. All patients will undergo balloon angioplasty for anterior or posterior tibial artery lesions, with the angiography-guided group aiming for optimal procedural results based on angiography, and the pressure wire-guided group aiming for optimal results based on both angiography and pressure gradient measurements.
  4. The primary efficacy endpoint is attainment of skin perfusion pressure ≥50 mmHg within 1-3 days after the procedure.
  5. Clinical follow-up will occur at 1, 3, and 6 months to assess wound healing and clinical events.
03

Conditions studied

  • Chronic Limb-Threatening Ischemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with chronic limb threatening ischemia (Rutherford 5)
  • Anterior tibial artery or posterior tibial artery lesions ≥ 10 cm Age ≥19 years

Exclusion criteria

Exclusion Criteria:

  • Acute limb ischemia
  • to antiplatelet or anticoagulation agents:

    1. Thrombocytopenia ( \<100,000/uL)
    2. Previous cerebral hemorrhage, GI bleeding, other reasons for increased bleeding risk within 6 months
  • Pregnant women or women with potential childbearing
  • \< 1 year
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Angiography-guided angioplasty

    In this group, balloon angioplasty will be performed on the target infrapopliteal artery lesion to achieve an optimal procedural result, as determined by angiography. Optimal results are defined as antegrade blood flow without residual stenosis \>50% or any flow-limiting dissection.

    Procedure: Angiography-guided angioplasty

  • Experimental
    Pressure wire-guided angioplasty

    In this gorup, balloon angioplasty will be performed on the target infrapopliteal artery lesions to achieve an optimal procedural result, as determined by the pressure gradient across the target lesion. An optimal procedural result is defined as pressure gradient less than 10 mmHg, measured using a Pressure Wire.

    Procedure: Pressure wire-guided angioplasty

Interventions

  • ProcedureAngiography-guided angioplasty

    Balloon angioplasty will be performed on the target infrapopliteal artery lesion to achieve an optimal procedural result, as determined by angiography. Optimal results are defined as antegrade blood flow without residual stenosis \>50% or any flow-limiting dissection.

  • ProcedurePressure wire-guided angioplasty

    Balloon angioplasty will be performed on the target infrapopliteal artery lesions to achieve an optimal procedural result, as determined by the pressure gradient across the target lesion. An optimal procedural result is defined as pressure gradient less than 10 mmHg, measured using a Pressure Wire.

06

What researchers measure

Primary outcomes

  1. Attainment rate of postprocedural skin perfusion pressure ≥50 mmHg

    within 3 days after the index endovascular therapy

    Time frame: Attainment rate of postprocedural skin perfusion pressure≥50 mmHg within 3 days after the indez endovascular therapy

07

Study locations

1 of 1 sites recruiting
  • Division of Cardiology, Severance Cardiovascular hospital Department of Internal Medicine, Yonsei University College of Medicine
    Seoul, South Korea
    Recruiting
    • young Guk ko, MD · Contactygkp@yuhs.ac · 82-02-2228-8451
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 17, 2025
StartActual
Oct 2, 2025
Primary completionEst.
Dec 29, 2027
CompletionEst.
Aug 29, 2028
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06879561
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Oct 2, 2025
Primary completion
Dec 29, 2027 (estimated)
Completion
Aug 29, 2028 (estimated)
Last update
Dec 2, 2025

Study contacts

Young-Guk Ko, MD. Division of Cardiology
Contact
ygko@yuhs.ac
+82-2-228-8451

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion